ArticlemSphere2019
Enhanced Immunogenicity and Protective Efficacy of a
Article in mSphere, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates.Journal of virology · 2026Article
- Consortium ofAntibiotics (Basel, Switzerland) · 2024Article
- Campylobacter jejuni virulence factors: update on emerging issues and trends.Journal of biomedical science · 2024Review
- Effect of the polysaccharide capsule and its heptose on the resistance of Campylobacter jejuni to innate immune defenses.MicrobiologyOpen · 2024Article
- Immunogenic characterization of AlPOClinical and experimental vaccine research · 2023Article
- Potentials of saponins-based adjuvants for nasal vaccines.Frontiers in immunology · 2023Review
- Glycosphingolipids (GSLs) fromMolecules (Basel, Switzerland) · 2022Article
- Current approaches to HIV vaccine development: a narrative review.Journal of the International AIDS Society · 2021Review
- Campylobacter sp.: Pathogenicity factors and prevention methods-new molecular targets for innovative antivirulence drugs?Applied microbiology and biotechnology · 2020Review
- Carbohydrate Immune Adjuvants in Subunit Vaccines.Pharmaceutics · 2020Review
- Evaluation of the protective efficacy of a Leishmania protein associated with distinct adjuvants against visceral leishmaniasis and in vitro immunogenicity in human cells.Parasitology research · 2020Article
- Article
- Army Liposome Formulation (ALF) family of vaccine adjuvants.Expert review of vaccines · 2020Review
- Impact of TJournal of virology · 2020Article
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.